Objective: To determine the frequency of "signature" chromosomal abnormalities in oncology workers handling anticancer drugs. Methods: Peripheral blood from health care personnel (N ϭ 109) was examined with probes for targets on chromosomes 5, 7, and 11. The effect of drug-handling frequency on chromosome abnormalities was assessed. Results: An excess of structural (0.18 vs 0.02; P ϭ 0.04) and total abnormalities (0.29 vs 0.04; P ϭ 0.01) of chromosome 5 was observed in the high-exposure group compared with the unexposed. Increased incidence rate ratios (IRRs) for abnormalities of chromosome 5 (IRR ϭ 1.24; P ϭ 0.01) and for either chromosome 5 or 7 (IRR ϭ 1.20; P ϭ 0.01) were obtained at 100 handling events. Effect sizes were augmented 2-to 4-fold when alkylating agent handling alone was considered. Conclusions: Biologically important exposure to genotoxic drugs is apparently occurring in oncology work settings despite reported use of safety practices.
T he DNA-damaging effects of treatment with anticancer chemotherapy resulting in therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myeloid leukemia (t-AML) have been recognized since the late 1970s. 1 Since then, nonrandom arrangements of chromosomal abnormalities in treated patients developing these conditions have been described and include two principal patterns: the loss of all or part (typically the long arm) of chromosomes 5 and 7, primarily after alkylating agent therapy and balanced translocations involving the long arm of chromosome 11 after topoisomerase II inhibitor treatment. 2 An array of less common patterns has also been described. 3 Moreover, in the late 1970s, as the use of these agents was on the increase, concern for the health of cancer caregivers, pharmacy, and nursing personnel who handled these drugs began to increase.
Early investigations sought to demonstrate or refute that exposure to these agents was occurring as a consequence of work duties. Falck et al 4 using the Ames assay were first to report a doseresponse relationship between the frequency of bacterial mutants induced in the urine of oncology nurses and their drug-exposure intensity. The mutant frequency declined over the weekend hiatus from work exposure and accrued during the workweek. A subsequent study using a similar measure of urinary mutant frequency reported an increase in pharmacy personnel preparing chemotherapy infusions when using a horizontal-flow cabinet, which exhausts into the breathing zone of the operator. This increase was prevented when a vertical-flow class II biological safety cabinet (BSC) was used, which captures and vents contaminated air through a high efficiency particulate air filter and away from the operator. 5, 6 Scores of such monitoring studies of affected health care workers (HCWs) examining various measures of genotoxic exposure have accrued over the past three decades, with most documenting excess genotoxic activity. [7] [8] [9] [10] [11] [12] [13] Some of these studies, however, reflected workplace conditions before the Occupational Safety and Health Administration guidance and consensus professional practice changes, which recommended but did not require the use of special handling and BSCs in the preparation of infusions, injections, and patient-ready drug products. These "safe-handling" policies were first promulgated in the mid-to-late 1980s 14, 15 and were updated subsequently. 16 -18 Importantly, however, these early studies documented the plausibility of biologically relevant genotoxic outcomes occurring as a result of workplace exposure.
HCWs are exposed to anticancer agents primarily through inhalation and dermal exposure routes. During the preparation of infusions, when diluent is added to a drug powder in a pressurized vial, fugitive aerosols can be generated. Dusts may also be generated with tablet crushing and during spill cleanup. Work surface contamination can facilitate skin exposure. 19, 20 Biological monitoring studies to detect the uptake of these drugs during occupational exposure have documented positive results in the urine of exposed workers in 17 of 19 studies performed. Four studies also reported positive urine results in nondrug-handling workers, implying secondary exposure from environmental contamination. 20 Of further concern is that a recent spate of publications reported positive urine biomonitoring results in study subjects despite their use of personal protective apparel and safehandling practices [21] [22] [23] [24] [25] suggesting that their exposure risk is still ongoing.
No previous studies have surveyed exposed workers for abnormalities of chromosomes 5, 7, and 11, the signature cytogenetic markers for many t-MDS/t-AMLs observed in treated patients. We assessed these agent-specific targets in our study of workers who handle cancer chemotherapy in the occupational setting. Because of the common use of alkylating agents, we hypothesized a priori that observable effects would be seen in chromosomes 5 or 7 or both if biologically important exposure to these genotoxic drugs was occurring.
MATERIALS AND METHODS

Study Design/Setting
As part of a larger study of HCW exposure to anticancer chemotherapy, a cohort of exposed and nonexposed HCWs was assembled from three US university hospital-based cancer centers. Each center endorsed use of safe-handling practices 16, 19 in the preparation and administration of cancer chemotherapy. This included drug mixing in a BSC, work practices that minimized drug aerosolization, and use of gloves during drug handling. One site also reported intermittent use of a closed system drug transfer device, which minimizes drug aerosol-primarily in the pharmacy.
Study Participants
Sixty-three oncology pharmacy and nursing personnel volunteered for the study and were frequency matched with 46 non-exposed pharmacy and nursing personnel by gender and age within 5 years. All participants completed informed consent procedures before participation. Inclusion criteria required that the exposed group had job duties handling chemotherapy for the past 6 months and in the week before assessment must have worked 24 hours handling drugs (either 3-8-hour shifts or 2-12-hour shifts). Handling tasks included intravenous infusion preparation, administration, other manipulation of the drugs, and contact with patient waste while receiving chemotherapy or spill cleanup. For the nonexposed group, a current job in nursing or pharmacy was required but not involving chemotherapy, which was ascertained during recruitment meetings and interview by study nurses.
Exclusion criteria included persons currently smoking, receiving chemotherapy, or who had previously received chemotherapy or radiation therapy. Persons who used other genotoxic pharmaceuticals (eg, accutane) and men undergoing hormonal therapy within the past 6 months were also excluded. All participants gave informed consent to participate, and the study protocol was approved by the institutional review boards of all three institutions.
Data Collection
Questionnaire data collected on all study participants included medical history, personal medications, radiograph exposure history, other social habits (alcohol use and hobbies), and a detailed history of work practices used. A study nurse reviewed the questionnaire with each participant during the data collection period at each facility.
Exposure Assessment
Six-Week Drug-Handling Diary
Exposed participants completed a 6-week diary of drughandling events, which included the name and dose of drug handled, the type of event (drug reconstitution or administration), and the use of protective apparel or equipment (such as gloves, gowns, eye protection, or mask). This 6-week period ended on the day the participant's blood was drawn. This approach to assess exposure was used for several reasons. Participants were exposed to Ͼ40 different drugs, many of which were genotoxic and even within the alkylating and topoisomerase II inhibitor families, multiple agents were used, making personal breathing zone sampling for multiple drugs unfeasible. Moreover, air sampling for these drugs has been technically challenging, and its utility in this context has been disputed. 26 Air sampling also fails to account for dermal exposure, which is thought to be important in this setting. 23, 27 Therefore, subject-specific exposure was calculated based on the frequency of drug handling such that mixing one infusion, administering one infusion or injection, or handling an infusion bag for inspection or dose checking were each tallied as one event. This type of frequency tally is an accepted approach for exposure assessment in mixed exposure cases such as this. 28 
Blood Specimen Collection
The study nurse obtained blood from all participants through venipuncture in heparinized containers and transported it at room temperature directly or through overnight mail to the cytogenetics laboratory for analysis.
Blood Cell Cultures and Slide Preparation
Standard blood culture and harvest protocols were used to prepare metaphase spreads similar to those described by Zhang. 29 Blood cells were incubated at 37°C in a 5% CO 2 moist atmosphere and harvested 72 hours after culture initiation. Colcemid (0.1 g/mL; Gibco BRL, Grand Island, NY) was added 1.5 hours before harvesting to obtain adequate numbers of metaphase spreads. After hypotonic treatment (0.075 M KCl) for 30 minutes at 37°C, the cells were fixed with Carnoy's solution. The fixed cells were then dropped onto glass slides and placed on a slide warmer to dry.
Fluorescence In Situ Hybridization
Fluorescent in situ hybridization (FISH) analysis of PHAstimulated metaphase cells was conducted by the University of Maryland, School of Medicine, Cytogenetics Laboratory (Baltimore, MD) using the method described by Zhang et al 29, 30 and blind to the exposure status of participant samples. FISH was performed using a D5S721(5p15.2)/EGR1(5q31) probe set, an ELN(7q11.23)/ D7S486(7q31) probe set, and a CEP11/MLL(11q23) probe set to detect abnormalities involving chromosomes 5, 7, and 11, respectively. For each probe set, 200 metaphase cells from each subject were available for scoring (a limitation of the blood volume available). Probes were obtained from Vysis, Downers Grove, IL, and validated in accordance with the recommendations of the American College of Medical Genetics. Hybridization procedures were performed according to the manufacturer's instructions, and images were acquired using an Olympus Provis fluorescence microscope with Applied Imaging system (Applied Imaging International Ltd, Newcastle upon Tyne, England).
Analysis of FISH Results
Abnormalities detectable by the three probe sets included aneuploidy, complete and partial deletions involving 5p, 5q, 7q, and 11q, breaks, and translocations. Frequencies of these chromosome abnormalities observed in participants ranged from 0 abnormalities per 200 cells (no abnormalities) to 3 per 200 cells counted. Because each of these abnormalities has been associated with t-MDS/t-AML, 3, 31 we looked at them separately and combined such that, we summed abnormalities for each numbered chromosome and also summed abnormalities by category as either numerical (a copy number difference) or structural (breaks, deletions, isochromes, and translocations).
Statistical Methods
The relation between drug-handling frequency (the independent variable) and chromosomal abnormality counts from the FISH assay (the dependent variable) was examined by using exposure frequency as both a categorical (no, low, and high exposure) and a continuous variable (handling event counts).
Categorical analysis was accomplished by stratifying the 109 participants into exposure categories based on frequency of drug-handling events. The nonexposed control group was first compared with the exposed group as a whole and then with the exposed population, which was stratified into 1) a low-exposed group or 2) a highly exposed group at a "cut point" of 153, the mean number of drug handling events recorded by the participants in the 6-week diary.
Chromosomal abnormality frequencies were compared by exposure category using Poisson regression. This allowed for comparison of exposure group results while adjusting for covariates of study site location, gender, age, environmental tobacco smoke, and radiation exposure, where the model permitted. The x-ray film exposure history was converted to total dose (mSv) based on an estimated 0.02 mSv for an x-ray film and 8 mSv for CT. 32 In certain cases, all covariates could not be included in the models. Outcome measures by exposure categories were compared using the 2 analysis. The Poisson distribution and the log link function were then used to model the associations between exposure (drug-handling frequencies) as a continuous variable and chromosomal abnormality outcomes. Poisson regression was used as we were dealing with counts and relatively rare events. The GENMOD procedure (SAS version 9.1; SAS Institute, Inc, Cary, NC) was used to fit the models. Two measures of exposure were used, the number of handling events of all anticancer drugs and the number of handling events of alkylating agents only.
The covariates used in the model were those listed above. In exploratory data analyses, race and alcohol intake were found not to be statistically significantly related to the FISH outcomes and were therefore dropped from the models. Models for abnormalities in chromosome 5 did not contain environmental tobacco smoke exposure as a covariate due to quasi-complete separation of the data leading to some empty cells. This necessitated its removal from the model. 33 Regression coefficients obtained from the Poisson model were used to estimate the increase in frequency of chromosome abnormalities as the number of handling events increases, expressed as an incidence rate ratio (IRR). 34 Examples of estimated IRRs for chromosomal abnormality increases were calculated for 100 and 500 drug-handling events. IRRs were also calculated for estimates of the increase in chromosomal abnormality frequency as a function of alkylating drug handling alone at 100 and 200 handling events.
RESULTS
The study participants included oncology personnel who handle anticancer chemotherapy in the course of their work duties with the job titles of nurse, pharmacist, and pharmacy technician (the exposed) and personnel with the same job titles but without exposure recruited from other departments of the three participating hospitals. Demographics of these participants are given in Table 1 . Table 2 describes a summary of drug-handling events recorded in participant diaries showing a mean frequency of ϳ153 events during the 6-week period with a range from one handling event to a maximum of 914 drug encounters. The alkylating drug-handling events representing about a quarter of all drugs handled is also shown. Covariates of radiation and "second-hand" environmental tobacco smoke exposure are also displayed.
The frequency of drug encounters by drug class was also derived from the drug-handling diaries for almost 10,000 handling events recorded during the 6-week study period (Table 3) . Across all job titles, the alkylating agents were most frequently handled at 23% of total encounters, followed closely by the mitotic inhibitors and antimetabolites at 21% and 20%, respectively. The topoisomerase II inhibitors contributed only 4%, and the anthracycline antibiotics contributed 9% to the total.
In exploratory analyses, categorical comparisons of the chromosomal damage frequencies for the nonexposed group (N ϭ 46) compared with the total exposed group (N ϭ 63) showed no statistically significant differences for any endpoint (data not shown). Job title classification (nurse and pharmacist) also showed no statistically significant differences between groups for any of the chromosomal abnormalities examined in this study.
The comparison of mean frequencies of chromosomal damage by exposure category (no exposure, low exposure, and high exposure) is displayed in Table 4 . Here, the nonexposed group is compared with each strata of the exposed group separately. As can be seen, the low-exposed group displays no statistically different results for chromosomal abnormality frequency compared with the nonexposed group. The highly exposed group, however, when compared with the nonexposed has a general trend of higher abnormality frequencies for almost every outcome examined, reaching statistical significance with excesses in structural abnormalities of chromosome 5 (0.02 vs 0.18; P ϭ 0.04 for the nonexposed vs the highly exposed, respectively) and total changes in chromosome 5 (0.04 vs 0.29; P ϭ 0.01). Table 5 displays the IRRs for predicted chromosomal abnormalities derived from regression coefficients obtained from the The values are represented as N (%). Poisson modeling of the chromosome abnormality data. Because abnormalities of both chromosomes 5 and 7 have been related to t-MDS/t-AML, we planned to examine abnormalities of these two chromosomes together and separately. Abnormalities of either chromosome 5 or 7 were significantly increased per drug-handling event such that at 100 handling events, a 20% increase in chromosome abnormality frequency is observed compared with control subjects without exposure (IRR ϭ 1.2; P ϭ 0.01). Recall that 100 is less than the mean number of handling events of 153 reported by participants during the 6-week study period. Twenty-three exposed participants had handling events Ն100. At 500 handling events (7 of 63 exposed participants), the increase in chromosome 5 or 7 abnormalities is almost 2.5-fold greater than that observed in the controls (IRR ϭ 2.49; P ϭ 0.01). Similar effect sizes are seen for abnormalities of chromosome 5 alone, with an IRR at 100 handling events of 1.24 and at 500 events of 2.94 (P ϭ 0.01). Drug-handling frequency also influences the frequency of abnormalities in chromosome 7 alone with an IRR at 100 handling events of 1.13 and at 500 events of 1.88, but this result does not reach statistical significance (P ϭ 0.27). Little effect from drug-handling exposure was observed on chromosome 11 abnormalities. Table 6 was constructed in a similar fashion as was Table 5 but using only alkylating agent handling events as the exposure measure. Recall that alkylating agents represented about a quarter of all drugs handled by participants, and thus, the mean and range of handling events for this drug class is reduced compared with that used in Table 5 for all drug classes. The IRRs here reflect an increase in chromosomal abnormalities specific to alkylating agent handling. At 100 handling events (corresponding to the top nine exposed participants), the IRRs observed for each type of abnormality for chromosomes 5 or 7 or both are 2-to 3-fold higher than those shown in Table 5 derived from the effect of any drughandling event. At the 200 handling event level (three exposed participants are within 10% of this level), the effect seems more pronounced. Statistically significant increases in chromosomal damage per alkylating drug handling event are seen for Chromosome 5 or 7 with an IRR at 200 handling events of 6.86 (P ϭ 0.001) and for chromosome 5 alone with an IRR at 200 handling events of 8.54 (P ϭ 0.01). Note that for chromosome 7 abnormalities at 100 handling events, the IRR ϭ 2.31 and at 200 handling events the IRR ϭ 5.34 are seen and approach significance (P ϭ 0.11).
DISCUSSION
t-AML developing after treatment with genotoxic chemotherapy currently accounts for ϳ10% to 20% of all AML cases. 35 Although t-AMLs are most commonly observed and well characterized after alkylating agent or topoisomerase II inhibitor treatment, 36 other drug classes including the anthracyclines 37 and mitotic inhibitors 38 are genotoxic or aneugenic and several drugs not in the alkylating or topoisomerase II inhibitor classes are known or presumed human carcinogens according to the International Agency for Research on Cancer. 39 This suggests a possible role in producing adverse genotoxic effects for these other drug classes as well.
"Induced" leukemia has also been described in various occupational cohorts exposed to DNA-damaging agents such as ionizing radiation and benzene. 40, 41 It was, therefore, not surprising that concern about the potential for induced hematotoxic outcomes in oncology personnel exposed to alkylating and other DNAdamaging anticancer agents would arise with the recognition of t-AML in treated patients. 42 Because leukemia patients represent the final expression in an "exposure-effect" pathway 43 of leukemogenesis, they have been considered "positive controls" for scenarios of workers exposed to leukemogens, most explicitly for oncology personnel. 44 Therefore, surveillance approaches for occupational cohorts have included laboratory techniques used in the clinical diagnosis and treatment of leukemia patients due to the shared hematopoietic targets of concern and the leukemogenic nature of many workplace genotoxicants.
One such clinical tool used in leukemia patient management is the FISH technique, which complements conventional cytogenetic banding and supplies additional detail in characterizing region-specific chromosomal targets of leukemogens. 45 It has been performed on both bone marrow (BM)-derived and peripheral blood (PB) cells and has also been applied in occupational surveillance studies to assess chromosomes involved in leukemogenesis. 29,46 -49 The advantage conferred by using PB cells and thereby avoiding the need for invasive BM aspirate procedures has driven studies of paired BM and PB samples looking for concordance. We have previously shown, for example, that PB FISH results (in both unstimulated and phytohemagglutinin-stimulated lymphocytes) were generally similar to BM results by both classical karyotyping and by FISH on BM cells in a serial cohort of 10 AML patients. 44 As the concordance of these methods and cell types are solidified, FISH will have an increasing role both for the clinical management of the leukemia patient and in occupational surveillance, where BM aspiration would be unethical for surveillance purposes.
Applying this clinically useful tool to occupational surveillance, we report here dose-dependent excesses of aberrations in chromosomes 5 and 7 as a function of anticancer drug-handling frequency. Although we used a 6-week time frame to collect drug-handling history in real time to eliminate recall bias, it is important to note that Ͼ90% of participants reported similar employment and 75% similar drug-handling intensity over the previous year and that the average duration of employment in oncology work was Ͼ7 years. This suggests that their exposure Bold values are those reaching statistical significance. *IRRs describe association between chromosome abnormality rates predicted by the model at select drug-handling frequencies compared with chromosome abnormality rates at 0 drug-handling events (controls).
†Reported P values are from 2 test.
opportunity occurred chronically over a protracted time frame likely sufficient to accumulate the stable aberrations that the FISH technique detects. The 2-to 4-fold increase in IRRs from alkylating agent handling, seen in Table 6 , illustrates an amplification of effect and possible targeting of chromosomes 5 and 7 conferred by the alkylating agent exposure even beyond that observed in Table 5 resulting from the effect on chromosome damage frequency from any drug class handled. Both clastogenic changes and aneuploidy of chromosomes 5 and 7 were detected by FISH, and both types of abnormalities are observed in t-AML related to alkylating agent treatment. 36 This specificity of effect reported here complements the body of evidence in the literature describing work-related increases in more nonspecific markers of genotoxic exposure reported in oncology personnel. 8, 20 Regarding the extremely weak correlation with drug-handling events and aberrations of chromosome 11, we note that the topoisomerase II inhibitors represented just 4% of the total handling events. Even with some contribution to the topoisomerase II inhibitor effect from some of the anthracyclines (9% of total handling events), the handling frequency for this class of agents is far surpassed by the alkylating agent frequency.
We noted no significant differences for any of the outcomes examined between job title classifications (eg, nurse and pharmacist) during preliminary analysis. This is interesting especially because pharmacists, as a category, had a higher handling event frequency than the nurses (Table 3 ). The lack of difference in outcomes might suggest that there is some difference in the nurses' intensity of exposure versus a pharmacist's during a handling event.
Recall from Table 2 , however, that the standard deviation associated with the mean number of participants' handling events was large, suggesting wide variability between individuals thus making categorical comparisons difficult. Moreover, our findings associating frequency of drug handling with excesses in chromosomal abnormalities seem to be only among the highest-exposed participants ( Table 4 ), such that the low-exposed group was not significantly different than controls for the outcomes of interest. This suggests that a possible "threshold" effect is operating. This too could be obscured by the more crude categorical analysis.
The strength of the overall study findings would obviously be bolstered by improved power, possibly allowing the trend in chromosome 7 abnormalities to reach significance. In addition, raising the number of lymphocytes counted beyond 200 cells would help in this regard. We were, however, limited by blood volume available, and at the time the study was designed, the cell count number was considered sufficient. Although the drug-handling history was self-reported, a potential limitation, it was recorded daily thus minimizing recall bias. Evenwith these limitations, however, we did find statistically significant results that were identified a priori in our hypothesis.
The biologic plausibility of the dose-dependent excess of aberrations observed in this study is further supported by environmental sampling results for fugitive drug aerosol found on work surfaces in ϳ60% of Ͼ140 samples taken. Moreover, biomonitoring revealed abnormal urine results for cyclophosphamide (two workers) and paclitaxel (one worker) among study participants. 50 These findings suggest that biologically important exposure to genotoxic drugs is occurring in work settings despite endorsement by hospitals of "safe-handling" practices.
As these findings raise questions about individual or facility compliance or both with safe-handling guidelines, institutions must effectively monitor and ensure that work practices are consistent with these recommendations and provide up to date education about exposure risk.
There are important public health implications derived from the findings of this study. Although compliance improvements can be promoted at the individual facility level, the adequacy of protection that the current safe-handling guidelines offer must also be scrutinized. The risk to caregivers that seems to remain, even under current working conditions, must be minimized while providing these lifesaving but toxic therapies to patients.
